If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEPATOLOGY<br /> Supplement • emjreviews.com<br /> ILC ANNUAL CONGRESS 2014<br /> EXCEL LONDON EXHIBITION & CONVENTION CENTRE, LONDON, UK<br /> 9TH - 13TH APRIL 2014<br /> International Liver Congress 2014<br /> Meeting Highlights<br /> INTERNATIONAL LIVER CONGRESS 2014<br /> MEETING HIGHLIGHTS<br /> *Graham R. Foster,1 **Jean-Michel Pawlotsky2,3<br /> 1. Queen Mary University of London, Institute of Cell and Molecular Science, London, UK<br /> 2. National Reference Center for Viral Hepatitis B, C, and D, Department of Virology, Hôpital Henri<br /> Mondor, Université Paris-Est, Créteil, France<br /> 3. INSERM U955, Créteil, France<br /> *Correspondence to g.r.foster@qmul.ac.uk<br /> **Correspondence to jean-michel.pawlotsky@hmn.aphp<a title="Hepatology Supplement 2014 page 1" href="http://viewer.zmags.com/publication/f07dd238?page=1"> HEPATOLOGY Supplement • emjreviews.com ILC ANNUAL</a> <a title="Hepatology Supplement 2014 page 2" href="http://viewer.zmags.com/publication/f07dd238?page=2"> INTERNATIONAL LIVER CONGRESS 2014 </a> <a title="Hepatology Supplement 2014 page 3" href="http://viewer.zmags.com/publication/f07dd238?page=3"> Liver Congress (ILC) meeting led to optimis</a> <a title="Hepatology Supplement 2014 page 4" href="http://viewer.zmags.com/publication/f07dd238?page=4"> Table 1 continued. Patient characteristics Previo</a> <a title="Hepatology Supplement 2014 page 5" href="http://viewer.zmags.com/publication/f07dd238?page=5"> Table 2: Key results from studies presented at th</a> <a title="Hepatology Supplement 2014 page 6" href="http://viewer.zmags.com/publication/f07dd238?page=6"> Table 2 continued. Study Treatment arms T</a> <a title="Hepatology Supplement 2014 page 7" href="http://viewer.zmags.com/publication/f07dd238?page=7"> naïve non-cirrhotic patients, who received 4</a> <a title="Hepatology Supplement 2014 page 8" href="http://viewer.zmags.com/publication/f07dd238?page=8"> still represent a life-saving option in this crit</a> <a title="Hepatology Supplement 2014 page 9" href="http://viewer.zmags.com/publication/f07dd238?page=9"> Table 3 continued. Study Treatment arms TN/TE</a> <a title="Hepatology Supplement 2014 page 10" href="http://viewer.zmags.com/publication/f07dd238?page=10"> SAPPHIRE II SAPPHIRE II was a double-blind, place</a> <a title="Hepatology Supplement 2014 page 11" href="http://viewer.zmags.com/publication/f07dd238?page=11"> to these patient categories, as well as ongoing P</a> <a title="Hepatology Supplement 2014 page 12" href="http://viewer.zmags.com/publication/f07dd238?page=12"> Table 4 continued. Study Treatment arms TN/TE</a> <a title="Hepatology Supplement 2014 page 13" href="http://viewer.zmags.com/publication/f07dd238?page=13"> Table 4 continued. Study Treatment arms TN/TE</a> <a title="Hepatology Supplement 2014 page 14" href="http://viewer.zmags.com/publication/f07dd238?page=14"> REFERENCES 1. Mangia A et al. All oral fixed-dose</a> <a title="Hepatology Supplement 2014 page 15" href="http://viewer.zmags.com/publication/f07dd238?page=15"> 31. Wantuck JM et al. Review article: the epidemi</a>